Table 1.
Mean plasma CART-LI concentration (picomoles per liter), sd, number of patients with positive test, and sensitivity of CART, CgA, and CgB assays against disease status (stable or progressive) of patients with known neuroendocrine tumors
| Site of NET | Disease status | n | CART
|
CgA
|
CgB
|
|||
|---|---|---|---|---|---|---|---|---|
| Mean (sd) | +ve (%) | Mean (sd) | +ve (%) | Mean (sd) | +ve (%) | |||
| Midgut | Stable | 24 | 250 (348) | 7 (29) | 490 (342) | 24 (100) | 120 (43) | 6 (25) |
| Progressive | 27 | 447 (429) | 16 (60) | 697 (396) | 25 (93) | 147 (57) | 12 (44) | |
| Pancreatic | Stable | 18 | 426 (443) | 8 (44) | 352 (409) | 12 (67) | 168 (114) | 11 (61) |
| Progressive | 20 | 625 (348) | 19 (95) | 379 (362) | 16 (80) | 166 (57) | 12 (60) | |
| Unknown primary | Stable | 12 | 520 (455) | 7 (58) | 622 (362) | 12 (100) | 202 (114) | 8 (67) |
| Progressive | 12 | 606 (434) | 8 (67) | 794 (338) | 11 (92) | 209 (76) | 9 (75) | |
| Hindgut | Stable | 4 | 279 (326) | 2 (50) | 361 (438) | 3 (75) | 142 (27) | 1 (25) |
| Progressive | 1 | 70 | 0 (0) | 141 | 1 (100) | 89 | 0 (0) | |
| Lung | Stable | 4 | 532 (540) | 2 (50) | 299 (468) | 2 (50) | 127 (85) | 2 (50) |
| Progressive | 1 | 270 | 1 (100) | 60 | 0 (0) | 49 | 0 (0) | |
| Thymic | Stable | 2 | 58 (27) | 0 (0) | 37 (5) | 0 (0) | 61 (9) | 0 (0) |
| Progressive | 0 | |||||||
| Para-ganglioma | Stable | 1 | 1000 | 1 (100) | 153 | 1 (100) | 196 | 1 (100) |
| Progressive | 1 | 1000 | 1 (100) | 184 | 1 (100) | 161 | 1 (100) | |
| Gastric | Stable | 2 | 133 (103) | 1 (50) | 124 (77) | 2 (100) | 133 (29) | 1 (50) |
| Progressive | 0 | |||||||
| Ovary | Stable | 1 | 77 | 0 (0) | 1000 | 1 (100) | 157 | 1 (100) |
| Progressive | 0 | |||||||
| Renal | Stable | 0 | ||||||
| Progressive | 1 | 74 | 0 (0) | 50 | 0 (0) | 180 | 1 (100) | |
| All sites | Stable | 66 | 372 (411) | 28 (42) | 448 (383) | 57 (86) | 150 (88) | 30 (46) |
| Progressive | 54 | 535 (419) | 36 (67) | 592 (420) | 46 (85) | 167 (65) | 32 (60) | |
CART +ve, Plasma CART-LI greater than 150 pmol/liter; CgA +ve, plasma CgA greater than 60 pmol/liter; CgB +ve, plasma CgB greater than 150 pmol/liter.